Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of antiresorptive treatment on bone loss in spinal cord injury patients
2007-002744-22Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of alendronate in Spinal Cord Abnormalities, osteoporosis and Spinal cord and nerve root disorders, sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Bone mineral density at total hip (proximal femur upper extremity). Started Sep 2007; status: active.
02
Drugs
alendronate
03
Conditions
Spinal Cord AbnormalitiesosteoporosisSpinal cord and nerve root disorders
Beyond the preview
Go deeper on 2007-002744-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002744-22.